Fund chief to kickstart fundamental changes in antibiotics market

Even though Novo Nordisk-funded AMR Action Fund was created to finance the development of antibiotics, CEO Henry Skinner expects that a lot of the fund's work will also involve raising awareness on the deepening lack of new antibiotics.

AMR Action Fund Henry Skinner | Photo: AMR Action Fund / PR

Henry Skinner struggles to hold himself back when discussing current issues with the antibiotics market. As the newly appointed CEO for the antimicrobial resistance research fund AMR Action Fund, being passionate about this area is sort of embedded in his job description.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs